Photo (from left to right): Daniel Pipeleers, Ed Baetge, Willem de Vos, Stephen Friend, Stefan Catsicas, Rudolf Tanzi, Barry Halliwell, Rudolf Aebersold

Lausanne, Switzerland, October 6th, 2014 - The second meeting of the NIHS Scientific Advisory Board  took place on 11 and 12 September 2014. The SAB comprises six of the world’s leading experts in areas of interest to the NIHS:

  • Professor Rudolf Aebersold, Head of the Institute of Molecular Systems Biology, ETH, Zürich
  • Dr Stephen Friend, Physician, scientist, entrepreneur & innovator, Sage Bionetworks
  • Professor Barry Halliwell, Deputy President (Research and Technology), National University of Singapore
  • Professor Daniel Pipeleers, Director Diabetes Research Centre, Brussels Free University, Belgium
  • Professor Rudolf Tanzi, Prof of Neurology, Harvard University and Director of the Genetics and Aging Research Unit, Massachusetts General Hospital
  • Professor Willem De Vos, Prof of Microbiology, Wageningen University, The Netherlands

The purpose of the meeting was to review the NIHS scientific strategy with a specific focus on the Institute’s top projects, as well as hot topics for promising projects with possible high impact in the future.

In his introductory remarks, Stefan Catsicas, CTO of Nestlé, said that science and technology are at the heart of Nestlé’s Nutrition Health and Wellness journey, and that one question for the SAB is: "What is the right balance between fundamental science and leveraging it into our products?"

Ed Baetge, Head of NIHS, outlined the NIHS mission, strategy and roadmap and then the NIHS team presented their work, providing a thorough overview of the Institute’s scientific approach in the key areas of Metabolic Health (weight management/obesity and diabetes), Systems Nutrition&Health, Cognitive Health and Ageing,  and Gastro-Intestinal Health and Microbiome.

After the scientific sessions, the SAB conducted their closed session to develop their key feedback on the programs scientific approach and the NIHS’s longer-term strategy.